-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Aberrant DUSP6-RSK1 Signaling Axis Mediates Treatment Resistance and Disease Progression in Myeloproliferative Neoplasms

Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
Program: Scientific Workshops
Session: Translational and Post-translational Mechanisms
Friday, December 6, 2024, 3:35 PM-4:16 PM

Stephen Oh, MD, PhD

Washington University School of Medicine, Saint Louis, MO

Disclosures: Oh: Novartis: Consultancy; Kartos Therapeutics: Consultancy; CTI BioPharma: Consultancy; Celgene/Bristol Myers Squibb: Consultancy; Disc Medicine: Consultancy; Blueprint Medicines: Consultancy; PharmaEssentia: Consultancy; Constellation: Consultancy; Geron: Consultancy; AbbVie: Consultancy; Sierra Oncology: Consultancy; Incyte: Consultancy.

See more of: Translational and Post-translational Mechanisms
See more of: Scientific Workshop on Therapy Resistance Mechanisms in Blood Malignancies
See more of: Scientific Workshops
<< Previous Presentation | Next Presentation >>